Reed Spills Secrets on Cancer Treatment His Name Almost Forgotten
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. The venture outfit had just been founded a year prior to that, and despite the challenges facing the industry, it's now boasting a team of 17 employees. This rapid growth is a stark contrast to when we last spoke with Jobs, who warned at the time that biotech was still reeling from its recent downturn.
In an interview with TechCrunch Disrupt, Jobs attributed Yosemite's success to a cluster of blockbuster drugs all losing patent protection in roughly the same window. This created new opportunities for the firm to develop and market its own cancer treatment solutions. "I didn't expect Yosemite to be moving this fast," Jobs said, noting that the company has already started developing several promising treatments.
With AI taking center stage at Yosemite, it's clear that the firm is committed to revolutionizing the way biotech companies approach development and commercialization. Jobs' words have come full circle, as he now sees AI playing a crucial role in bringing new cancer treatment solutions to market. As the tech industry continues to evolve, it will be interesting to see how Yosemite's innovative approaches pay off in the years to come.